US Patent 10,066,017 Claims and U.S. Patent Landscape for IL-4R Antibody Plus Intranasal Corticosteroid in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
US Patent 10,066,017 centers on combination treatment of chronic sinusitis with nasal polyps (CRSwNP/CSwNP) using an IL-4 receptor (IL-4R) binding antibody (explicitly including dupilumab) together with maintenance intranasal corticosteroid (INCS), with specific antibody CDR sequence pairings (SEQ ID NOs: 1–2 for variable-region pairs; and SEQ ID NOs: 3–5 heavy-chain CDRs and SEQ ID NOs: 6–8 light-chain CDRs), dosing ranges, and patient phenotypes/assessments.
Core takeaways
- The patent claims are largely composition-to-method-of-treatment “on-ramp” claims: they tie a specific IL-4R antibody binding pair to a specific clinical setting (maintenance INCS for CSwNP) and specific patient and endpoint parameters (e.g., ≥5 polyps with ≥2 per nostril; symptom/NPIF improvement; reduced oral steroids or surgery).
- Independent claim 1 is written to cover any subject treated with the specified IL-4R antibody plus maintenance INCS for CSwNP, using a CDR-defined antibody variant set.
- Several dependent claims harden coverage around dosing regimens, subcutaneous administration, specific INCS duration coupling, and mometasone furoate.
- The landscape risk hinges on whether earlier dupilumab/IL-4R antibody patents already disclose the same clinical combination and regimen, and whether later entrants (biosimilars or generics of INCS) can design around the CDR-defined antibody limitation or the combination-with-maintenance-INCS limitation.
What is US Patent 10,066,017 and what do its claims cover?
Direct answer: US Patent 10,066,017 claims methods for treating chronic sinusitis with nasal polyps using an IL-4R binding antibody (dupilumab or fragment) defined by specified CDRs/sequence pairs, in combination with one or more maintenance doses of intranasal corticosteroid (INCS).
Key claim architecture
- Independent claim 1 (method): administer IL-4R binding antibody/fragment with heavy/light variable region sequence pair defined by SEQ ID NOs: 1 and 2, plus maintenance doses of INCS, to treat CSwNP.
- Dependent claims 2–5: increase patient definition (≥5 polyps; ≥2 per nostril), refine dosing (200–600 mg initial; 200–400 mg maintenance; weekly or q2w), and specify CDR sub-sequences (light CDR SEQs 6–8; heavy CDR SEQs 3–5) and clinical improvements (smell, runny nose, post nasal drip, NPIF; congestion, discharge, facial pain, headache).
- Claims 6 and 12 and 19 and 33: explicitly include dupilumab (and antigen binding fragments).
- Claim 7: introduces a loading + maintenance scheme (loading 400–600 mg; maintenance 200–300 mg) plus INCS.
- Claims 12–17: expand to INCS administered for the duration of antibody administration and cover specific INCS type (claim 18: mometasone furoate nasal spray), plus dosing periodicity and improvement endpoints.
- Claims 22–24: recast as bilateral nasal polyposis with persistent symptoms despite INCS; adds polyposis severity endpoints and reduces need for oral steroids or surgery.
- Claims 25–27: enforce route/device constraints: subcutaneous administration, syringe, prefilled syringe or autoinjector.
- Claims 28–30: specify a 300 mg dosing scheme (q2w) and tie CDRs again.
- Claims 31–33: lock further on sequence identity: HCVR equals SEQ ID NO 1; LCVR equals SEQ ID NO 2; and an antibody comprising heavy chain SEQ ID NO 9 and light chain SEQ ID NO 10; explicitly “dupilumab”.
What matters for enforceability
- The claims are highly tethered to the antibody’s CDR-defined identity. A competitor must generally avoid equivalence by:
- using a materially different IL-4R-binding antibody/fragment (sequence/CDR mismatch), or
- avoiding the claimed combination (no maintenance INCS for the specified dosing/clinical intent), or
- avoiding the claimed patient phenotype and/or endpoints where those are required by the claim set being asserted (not all dependent claim elements must be present if only independent claims are asserted).
- The combination with INCS is broadly stated, which is the main “gap-bridging” feature: many prior dupilumab patents cover dupilumab monotherapy or background steroids, but the specific formulation of maintenance INCS during dupilumab is what converts the method into a narrower but still practically relevant clinical protocol.
Which IL-4R antibody is implicated: is US 10,066,017 effectively about dupilumab?
Direct answer: Yes. The claims expressly include dupilumab, while also defining an IL-4R antibody by variable region sequence pairings (SEQ ID NOs: 1–2) and specific CDR sets (heavy CDR SEQs 3–5; light CDR SEQs 6–8), and repeat explicit “dupilumab or an antigen binding fragment thereof” in multiple claims.
Claim hooks tying to dupilumab
- Claim 6: “antibody or antigen binding fragment … is dupilumab…”
- Claim 12: same in the broader loading/maintenance + INCS-duration construct.
- Claim 18: mometasone furoate nasal spray as example INCS.
- Claim 33: “antibody … comprises dupilumab or an antigen-binding fragment thereof.”
- Claim 31–32: explicitly maps HCVR/LCVR to SEQ ID NOs and heavy/light chain sequences.
Practical consequence
If the defined CDRs and variable-region pairs align to dupilumab’s known structure, the patent’s enforceability against dupilumab products is direct. If a biosimilar’s CDRs/sequence pair do not match (or differ enough to avoid infringement), the patent’s coverage becomes a structure-specific binding fight rather than a simple “same MOA” debate.
What specific combination regimen (loading, maintenance, and INCS) is claimed in US 10,066,017?
Direct answer: US 10,066,017 includes multiple dosing embodiments:
- Claim 1: initial 200–600 mg; maintenance 200–400 mg; dosing weekly or every two weeks.
- Claim 7: loading 400–600 mg; maintenance 200–300 mg.
- Claims 12, 14, 17, 19: INCS for duration of antibody administration; loading 400–600 mg and maintenance 200–300 mg; one week or two weeks; mometasone furoate in at least one dependent claim.
- Claims 21 and 9: maintenance frequently pegged at 300 mg in narrower embodiments.
- Claims 29: 300 mg loading and q2w 300 mg secondary doses.
Claim-by-claim dosing matrix
| Claim |
Antibody dosing (loading) |
Maintenance dose |
Schedule |
INCS timing/duration |
| 1 |
200–600 mg |
200–400 mg |
q7d or q2w |
“one or more maintenance doses” |
| 7 |
400–600 mg |
200–300 mg |
q7d or q2w implied by related claims; not fully specified in claim 7 text snippet |
INCS administered (no explicit “for duration” in claim 7 itself) |
| 9 |
n/a |
~300 mg |
q7d or q2w |
INCS included by claim 7 base |
| 12 |
400–600 mg |
200–300 mg |
q7d or q2w (claim 17) |
INCS administered “for the duration of administration” of antibody |
| 14 |
300 mg |
300 mg |
not specified in claim 14; tied to claim 17 |
INCS for duration (from claim 12) |
| 18 |
n/a |
n/a |
n/a |
INCS = mometasone furoate nasal spray |
| 19 |
400–600 mg |
200–300 mg |
not specified here; tied to claim 12 basis |
INCS for duration |
| 21 |
400–600 mg |
200–300 mg |
not specified in claim 21; tied to base |
INCS present |
| 22–24 / 25–27 / 28–30 |
300 mg embodiment in claims 28–30; route/subQ in 25 |
300 mg |
q2w in claim 29 |
INCS is background “despite INCS” construct |
| 29 |
300 mg |
300 mg |
once every two weeks |
from claim 22 construct |
Enforcement relevance
- Dependent claims around dosing windows and schedules increase infringement “lock-in” for parties following label-like protocols.
- The “INCS for duration” limitation in claim 12 is a narrower procedural requirement. An accused regimen that stops INCS earlier could still infringe claim 1, but may avoid claim 12/19-specific embodiments depending on how assertions are selected.
What patient phenotype and clinical endpoints are required (and how do they limit or strengthen the claims)?
Direct answer: Several claims require a specific baseline polyp burden (at least 5 nasal polyps with two or more in each nostril) and recite improvements in defined polypositis/chronic sinusitis parameters, including NPIF and symptom clusters such as loss of smell, runny nose, and post nasal drip.
Baseline phenotype hardening
- Claim 2 / 8 / 13: patient has ≥5 nasal polyps with ≥2 per nostril prior to administering steps.
This narrows claim scope for infringement if the accused population is broader (e.g., milder polyp burden). Still, the presence of other independent claims without the polyp-count limitation means a plaintiff could pick broader claim coverage depending on trial evidence.
Endpoint limitations
- Claim 5 / 11 / 16 / 19: improvement in nasal polyposis-associated parameters (loss of smell, runny nose, post nasal drip, NPIF) and chronic sinusitis-associated parameters (nasal congestion, decreased/lost sense of smell, anterior/posterior nasal discharge, facial pain, headache).
- Claim 23: expands to NC severity, endoscopic NPS, CT opacification, TSS, SNOT-22.
Clinical “proof” vs legal elements
In method claims, these endpoints can function as:
- an evidentiary narrative of treatment effect, and/or
- a required result/step depending on claim drafting and judicial interpretation.
The presence of a long list of parameters is typically a litigation lever: multiple endpoints can be used to meet the claim’s “improvement” requirement without being confined to a single scale.
Relief endpoints
- Claim 24: reduction in need for oral corticosteroids and/or nasal polyp surgery.
This adds practical value for health economics and payer discussions, and it can be critical for tying clinical data sets to the claimed outcome language.
What delivery/administration mechanics are claimed (route, device, and syringe)?
Direct answer: The patent includes subcutaneous administration and device constraints:
- subcutaneous in claim 25
- syringe in claim 26
- prefilled syringe or autoinjector in claim 27
Why this matters
These limitations can help establish infringement for a specific product presentation and administration workflow, but they also create design-around space if an alternative route or device is used that avoids these constraints. Independent claims 1/20/22 appear to emphasize administration but do not necessarily require syringe/device wording unless those dependent claims are asserted.
What is the relevant U.S. regulatory and Orange Book context for this combination?
Direct answer: This patent claims a method using an IL-4R antibody that is explicitly dupilumab, plus intranasal corticosteroid therapy. The U.S. regulatory status and exclusivity landscape depends on dupilumab’s NDA/BLA and Orange Book listings, but the claims here are method-of-treatment claims rather than a composition listing per se.
Regulatory angle (practical)
- Even where a product is off-patent for composition, method-of-use claims like these can still block generic/biosimilar market entry for specific indications and dosing regimens.
- If a biosimilar or “interchangeable” product is approved, carve-outs or label differences may become central. A generic INCS is not at issue, since INCS is widely available; the patentability focus is the combination protocol with a specific IL-4R antibody.
(No Orange Book bibliographic details are provided in your prompt, so no specific Orange Book entry can be asserted here.)
How strong is the patent estate around US 10,066,017: what can drive validity vs vulnerability?
Direct answer: The strength of US 10,066,017 depends on (i) how early the underlying IL-4R antibody disclosures are, (ii) whether the combination of dupilumab with maintenance INCS in CRSwNP was already described, and (iii) whether the specific SEQ ID-defined CDR/variable-region pairing is novel and non-obvious over prior art antibody sequences.
Likely validity pressure points
- Antibody sequence/identity novelty
- The claims are tethered to specific CDR and variable region sequence pairs.
- If those sequences were already disclosed in earlier IL-4R antibodies (or if dupilumab-specific disclosures existed pre-filing), obviousness and anticipation risk rises.
- Combination obviousness
- CRSwNP treatment standard-of-care uses corticosteroids and sometimes biologics; IL-4R pathway modulation is known in related inflammatory settings.
- A key question in litigation is whether a POSA would combine an IL-4R antibody with maintenance INCS in CRSwNP with predictable results.
- Endpoint/result language
- Broad endpoint improvements may be challenged as non-limiting, or as result statements that do not impose meaningful process steps, depending on claim interpretation.
Likely enforceability advantages
- Explicit “dupilumab” inclusion plus sequence/label-level dosing constructs supports straightforward infringement for a commercial dupilumab regimen with INCS maintenance.
- The polyp-burden requirement in some dependent claims can align with typical trial inclusion criteria, improving evidentiary mapping.
What generic or biosimilar entry risks exist for this claim set?
Direct answer: INCS generics are not directly at risk. The risk is biosimilar/biobetter entry where:
- the candidate’s IL-4R binding antibody/fragment does not match the SEQ ID-defined variable/CDR identity enough to avoid literal infringement or equivalents, and/or
- the candidate’s proposed labeling and real-world use does not follow “maintenance INCS” protocols, and/or
- the candidate uses materially different loading/maintenance dosing schedules.
Design-around pathways that matter
- Structure design-around: diverge antibody CDRs/variable-region sequences so the SEQ-defined pairings are not met.
- Protocol design-around: avoid “INCS for duration” regimes if a court treats those as limiting; maintain baseline steroids only during initiation and stop thereafter.
- Indication/labeling: if exclusivity and method-of-use claims are enforced against an unapproved indication, litigation may restrict off-label use in the targeted CRSwNP subset.
How does US 10,066,017 compare with typical CRSwNP IL-4 pathway patent strategies?
Direct answer: The patent follows a common biologics patenting strategy: it combines (i) a specific antibody structure definition (CDRs/sequence pairs) with (ii) a specific disease context (CSwNP/CRSwNP), (iii) an add-on standard therapy (maintenance INCS), and (iv) dosing and endpoints.
Compared to broader MoA claims
- MoA-only patents tend to be harder to enforce against a biosimilar that shares IL-4R pathway binding.
- Structure-and-dosing-plus-combination claims like these shift leverage toward direct infringement mapping and regimen-specific evidence.
Key references and patent landscape conclusions (what the claims imply for litigation and licensing)
Licensing posture
- For any IL-4R biosimilar developer, US 10,066,017 functions as a combination-of-structure-and-protocol barrier. A licensing argument would likely focus on:
- whether the candidate’s CDR/variable pairing matches,
- whether the candidate’s clinical protocol maintains INCS during antibody treatment,
- and which dependent claims map to the intended label and real-world regimen.
Litigation posture
- A plaintiff can build a claim roadmap:
- assert independent claim 1 or claim 20 (less operationally constrained than the “for duration” embodiment),
- optionally add dependent claims (polyp burden, dosing, NPIF/smell outcomes, route/device) to reduce dispute space.
- A defense posture concentrates on the two main levers:
- antibody sequence equivalence and
- whether “maintenance INCS” is actually part of the accused regimen.
Key Takeaways
- US 10,066,017 is a method-of-treatment patent for CRSwNP/CSwNP combining an IL-4R binding antibody (explicitly dupilumab) with maintenance intranasal corticosteroid, using CDR/variable-region sequence-pair-defined antibody identity.
- The claim set includes multiple embodiments that align with practical clinical protocols: loading and maintenance dosing, weekly or q2w schedules, subcutaneous administration, and INCS administered during the antibody course (claim 12/19).
- Dependent claims tighten infringement maps using baseline polyp burden (≥5 total; ≥2 per nostril) and defined endpoints including NPIF and symptom clusters.
- Generic INCS supply does not solve infringement. The main market-entry risk sits with biosimilar IL-4R antibodies because the patent requires either sequence divergence or protocol divergence from “maintenance INCS” regimens.
FAQs
What is the infringement risk for a biosimilar that matches dupilumab’s IL-4R binding but uses different CDR sequences?
Infringement turns on whether the biosimilar meets the claimed CDR and variable-region pair limitations (literal or equivalents) and whether its CRSwNP use includes maintenance INCS during antibody dosing.
Do INCS generics or substitution of a different steroid avoid infringement?
Switching INCS might avoid a dependent claim limited to a specific INCS (e.g., mometasone furoate nasal spray), but it does not necessarily avoid infringement of broader claims requiring only “maintenance doses of INCS.”
Can a clinician reduce INCS duration to design around claim 12/19?
A regimen that stops INCS before antibody dosing ends could create a non-infringing pathway for embodiments that require INCS “for the duration,” while broader claims without that timing constraint remain a risk.
What endpoints matter most for proving the method claims?
Claims list multiple improvements, including NPIF, smell-related outcomes, congestion, discharge, facial pain, and headache, and in some embodiments broader clinical scales (endoscopic scores, CT opacification, SNOT-22, TSS). Evidence can be built across multiple listed parameters.
Is route or device essential to infringement?
Subcutaneous administration and syringe/device limitations appear in dependent claims. If asserted, route and device become important for infringement proof, but independent claims can still be asserted without those added constraints.
References
- US Patent 10,066,017 (claims provided in prompt; no bibliographic details supplied beyond the patent number).
